Published in Clin Transl Sci on August 01, 2012
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation (2007) 2.50
The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc Res (2010) 1.89
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation (2006) 1.81
Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation (2003) 1.78
Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice. Circ Res (2006) 1.73
Enhanced external counterpulsation in patients with heart failure: a multicenter feasibility study. Congest Heart Fail (2002) 1.66
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64
Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc Res (2004) 1.59
Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol (2005) 1.48
Does academic culture support translational research? Clin Transl Sci (2008) 1.47
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail (2003) 1.43
Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 1.42
Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation (2004) 1.36
TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol (2007) 1.36
Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation (2006) 1.30
Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation (2006) 1.30
Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol (2005) 1.28
Regulation of cardiac myocyte contractility by phospholemman: Na+/Ca2+ exchange versus Na+ -K+ -ATPase. Am J Physiol Heart Circ Physiol (2008) 1.22
Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart Circ Physiol (2005) 1.19
Calcium-dependent arrhythmias in transgenic mice with heart failure. Am J Physiol Heart Circ Physiol (2002) 1.17
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant (2002) 1.16
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.15
TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res (2008) 1.15
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol (2004) 1.14
Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. Am J Physiol Heart Circ Physiol (2004) 1.12
Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res (2005) 1.11
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci U S A (2011) 1.09
Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol (2005) 1.09
Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail (2002) 1.08
Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in mice. Am J Physiol Heart Circ Physiol (2002) 1.08
Gene expression profiling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis. J Mol Cell Cardiol (2004) 1.07
Induced overexpression of Na+/Ca2+ exchanger transgene: altered myocyte contractility, [Ca2+]i transients, SR Ca2+ contents, and action potential duration. Am J Physiol Heart Circ Physiol (2009) 1.06
Regulation of in vivo cardiac contractility by phospholemman: role of Na+/Ca2+ exchange. Am J Physiol Heart Circ Physiol (2010) 1.06
Phospholemman and beta-adrenergic stimulation in the heart. Am J Physiol Heart Circ Physiol (2009) 1.05
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol (2006) 1.03
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J (2005) 1.01
Constitutive overexpression of phosphomimetic phospholemman S68E mutant results in arrhythmias, early mortality, and heart failure: potential involvement of Na+/Ca2+ exchanger. Am J Physiol Heart Circ Physiol (2011) 1.01
Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res (2011) 1.01
Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation (2011) 1.00
A randomized clinical trial of the clinical effects of enhanced heart failure monitoring using a computer-based telephonic monitoring system in older minorities and women. J Card Fail (2008) 1.00
Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res (2002) 0.99
BAG3: a new player in the heart failure paradigm. Heart Fail Rev (2015) 0.98
Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail (2008) 0.98
MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol (2002) 0.97
Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy. Am J Physiol Heart Circ Physiol (2005) 0.96
Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3. J Card Fail (2010) 0.96
Cardioprotection of controlled and cardiac-specific over-expression of A(2A)-adenosine receptor in the pressure overload. PLoS One (2012) 0.95
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail (2008) 0.94
TRPM2 channels protect against cardiac ischemia-reperfusion injury: role of mitochondria. J Biol Chem (2014) 0.94
In the jungle. Clin Transl Sci (2010) 0.93
Identification of candidate long noncoding RNAs associated with left ventricular hypertrophy. Clin Transl Sci (2014) 0.92
Myocardial injury after ischemia-reperfusion in mice deficient in Akt2 is associated with increased cardiac macrophage density. Am J Physiol Heart Circ Physiol (2011) 0.92
A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation (2007) 0.91
The second member of transient receptor potential-melastatin channel family protects hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2013) 0.89
Cardiac-restricted overexpression of the A(2A)-adenosine receptor in FVB mice transiently increases contractile performance and rescues the heart failure phenotype in mice overexpressing the A(1)-adenosine receptor. Clin Transl Sci (2008) 0.88
Pharmacologic therapy of chronic heart failure. Am J Cardiovasc Drugs (2007) 0.88
Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol (2003) 0.88
Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail (2007) 0.87
Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardium. Am J Physiol Heart Circ Physiol (2002) 0.86
Induced overexpression of Na(+)/Ca(2+) exchanger does not aggravate myocardial dysfunction induced by transverse aortic constriction. J Card Fail (2013) 0.84
Coordinated regulation of cardiac Na(+)/Ca (2+) exchanger and Na (+)-K (+)-ATPase by phospholemman (FXYD1). Adv Exp Med Biol (2013) 0.84
CTS: a new discipline to catalyze the transfer of information. Clin Transl Sci (2008) 0.84
The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells. PLoS One (2011) 0.83
Effects of cardiac-restricted overexpression of the A(2A) adenosine receptor on adriamycin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol (2010) 0.83
Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol (2002) 0.83
Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells. Mol Pharmacol (2013) 0.83
Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clin Transl Sci (2010) 0.83
Enhanced external counterpulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial. Congest Heart Fail (2006) 0.83
Adenylyl cyclase: a new target for heart failure therapeutics. Circulation (2002) 0.83
Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch (2002) 0.82
The COMET trial. Congest Heart Fail (2005) 0.81
The balance between pro-apoptotic and anti-apoptotic pathways in the failing myocardium. Cardiovasc Toxicol (2003) 0.80
Rationale and design of the enoximone clinical trials program. J Card Fail (2005) 0.80
Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail (2009) 0.80
Enhanced external counterpulsation as treatment for chronic angina in patients with left ventricular dysfunction: a report from the International EECP Patient Registry (IEPR). Congest Heart Fail (2002) 0.80
Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2014) 0.79
Gβγ-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor α-induced cardiac β-adrenergic receptor dysfunction. Circulation (2013) 0.79
Commentary: Preparing internists for the 21st century: a response to the recent RAND survey of internal medicine education. Am J Med Qual (2011) 0.78
Upregulation of anticoagulant proteins, protein S and tissue factor pathway inhibitor, in the mouse myocardium with cardio-specific TNF-α overexpression. Am J Physiol Heart Circ Physiol (2012) 0.78
Re-envisioning our approach to research in academia. Clin Transl Sci (2008) 0.78
Modified inferior vena caval anastomosis to reduce tricuspid valve regurgitation after heart transplantation. Tex Heart Inst J (2007) 0.78
17 Beta-estradiol improves survival in male mice with cardiomyopathy induced by cardiac-specific tumor necrosis factor-alpha overexpression. J Interferon Cytokine Res (2005) 0.77
Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support. Clin Transl Sci (2008) 0.77
TNF alpha-still a therapeutic target. Clin Transl Sci (2008) 0.77
The clinical and translational science "tent". Clin Transl Sci (2010) 0.76
Advocacy: a new arena for the translational scientist. Clin Transl Sci (2011) 0.76
Assessment of infarct size and myocardial function in mice using transesophageal echocardiography. J Am Soc Echocardiogr (2004) 0.76
Safety of iodinated intravenous contrast medium administration in sickle cell disease. Am J Med (2012) 0.76